India Approves FabiSpray For COVID-19 Treatment
Glenmark Pharmaceuticals has launched a nasal spray in India for the treatment of COVID-19 in adult patients.
India has administered more than 170 crore COVID-19 vaccine doses so far. More than 75% of India's adult population has been fully vaccinated, as per government data. Now the Drugs Controller General of India (DCGI) has granted emergency use permission to single-dose Sputnik Light COVID-19 vaccine in India. This is the 8th COVID-19 vaccine in the country. Currently, the vaccines approved in the country are CORBEVAX, COVOVAX, ZYCOV D, COVISHIELD, COVAXIN, SPUTNIK (2 doses), Johnson & Johnson and now Sputnik Light. Now the DCGI has allowed Glenmark company to manufacture and sell a new medicine called FabiSpray. FabiSpray is a nasal spray that can be used for the treatment of COVID-19 in adult patients.
When sprayed in the nose, FabiSpray can kill the coronavirus in the nose and the lower respiratory tract.
It creates a barrier against the virus, preventing it from spreading to the lungs. Patients who are at high risk of COVID spreading in their bodies can use this medicine. FabiSpray was "safe and well-tolerated" among the volunteers involved in the trial. They are relatively easier to store, can be transported without refrigeration, and also remove injury risks that are associated with needle-based vaccines. Experts say that such a medicine can really help treat covid patients and put an end to the COVID pandemic. The nasal spray has already been approved by the European Union, Israel & Bahrain
